Levobunolol - Allergan

Drug Profile

Levobunolol - Allergan

Alternative Names: AG 901; AGN 101291; AGN 101291AL; Betagan; Bunolgan; Levobunolol ophthalmic - Allergan; Mirol; Vistagan; W 7000A

Latest Information Update: 04 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Allergan
  • Developer Allergan; Kaken Pharmaceutical; Kyorin Pharmaceutical
  • Class Antiglaucomas; Antihypertensives; Propanolamines; Small molecules
  • Mechanism of Action Beta-adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Glaucoma

Most Recent Events

  • 20 Mar 2001 Launched for Glaucoma in Japan (Ophthalmic)
  • 28 Jun 2000 New profile
  • 28 Jun 2000 Launched for Glaucoma in Argentina (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top